Stock Ratings Review: Gilead Sciences, Expedia, Alkermes, Edwards Sciences
Edwards Lifesciences Corp.(NYSE:EW): Jefferies recommends using any weakness in Edwards Lifesciences shares post the company’s Q4 results as a buying opportunity. The firm keeps a Buy rating on the name with a $92 price target.
Alkermes, Inc.(NASDAQ:ALKS): Jefferies said it has increased confidence in Alkermes following the company’s better than expected Q3 results and raised guidance. The firm believes Alkermes has gotten off to an excellent start post the merger with Elan Drug Technologies and keeps a Buy rating on name with an increased price target.
Gilead Sciences Inc.(NASDAQ:GILD): Gilead added to the short-term buy list at Deutsche Bank. After Gilead reported higher than expected Q4 revenue, Oppenheimer believes that the company’s 2012 guidance is conservative and expects sales of the company’s HIV treatments to continue to grow. The firm maintains an Outperform rating.
Expedia Inc.(NASDAQ:EXPE): Piper Jaffray sees the potential for slight upside to estimates when Expedia reports Q4 results on February 9. The firm upped its price target citing healthy industry trends and an improving trajectory for Expedia internationally while keeping an Overweight rating on the stock.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
To contact the reporter on this story: Derek Hoffman at firstname.lastname@example.org
To contact the editor responsible for this story: Damien Hoffman at email@example.com